A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2015
At a glance
- Drugs Cixutumumab (Primary) ; Temsirolimus (Primary)
- Indications Sarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 16 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jun 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 27 May 2014 Planned number of patients changed from 172 to 174 as reported by ClinicalTrials.gov.